Method of treatment using nanoparticulate ganaxolone formulations
In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
1. A method of treatment for depression, comprising administering to a human patient in need thereof an oral dosage form of stabilized ganaxolone particles comprising a therapeutically effective amount of ganaxolone, a hydrophilic polymer, a wetting agent, and an effective amount of a complexing agent selected from the group of small organic molecules having a molecular weight less than 550 and containing a moiety selected from the group consisting of a phenol moiety, an aromatic ester moiety and an aromatic acid moiety, the stabilized particles having a volume weighted median diameter (D50) of the particles from about 50 nm to about 500 nm, wherein the therapeutically effective amount of ganaxolone is sufficient to provide treatment to the human patient suffering from depression.
2. The method of claim 1 , wherein oral dosage form is a liquid dosage form and the stabilized ganaxolone particles are dispersed in an aqueous solution which further contains at least two preservatives in an amount sufficient to inhibit microbial growth.
3. The method of claim 1 , wherein the complexing agent stabilizes particle growth after an initial particle growth and endpoint is reached.
4. The method of claim 1 , wherein the hydrophilic polymer is in an amount from about 3% to about 50%, w/w, based on the weight of the dispersion.
5. The method of claim 1 , wherein the wetting agent is in an amount from about 0.01% to about 10%, w/w, based on the weight of the dispersion.
6. The method of claim 1 , wherein the ganaxolone is present in an amount greater than 50% to about 80%, based on the weight of the particles.
7. The method of claim 1 , wherein the volume weighted median diameter (D50) of the stabilized ganaxolone particles does not change by more than about 15% after 10 days of storage at room temperature.
8. The method of claim 1 , wherein the volume weighted median diameter (D50) of the stabilized ganaxolone particles does not change by more than about 15% after 40 days of storage at room temperature.
9. The method of claim 1 , wherein the volume weighted median diameter (D50) of the stabilized ganaxolone particles is from about 100 nm to about 450 nm.
10. The method of claim 6 , wherein the complexing agent is in an amount from about 0.05% to about 5%, w/w, based on the weight of the solid particles.
11. The method of claim 1 , wherein the complexing agent is selected from the group consisting of parabens, benzoic acid, methyl anthranilate, phenol, and pharmaceutically acceptable salts thereof and mixtures thereof.
12. The method of claim 10 , wherein the complexing agent is selected from the group consisting of parabens, benzoic acid, methyl anthranilate, phenol and pharmaceutically acceptable salts thereof and mixtures thereof.
13. The method of claim 1 , wherein the hydrophilic polymer is selected from the group consisting of a cellulosic polymer, a vinyl polymer and mixtures thereof and the wetting agent is selected from the group consisting of sodium lauryl sulfate, a pharmaceutically acceptable salt of docusate, or mixtures thereof.
14. The method of claim 1 , wherein the stabilized ganaxolone particles exhibit an increase in volume weighted median diameter (D50) of not more than about 150% when the particles are dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIP) at a concentration of 0.5 to 1 mg ganaxolone/mL and placed in a heated bath at 36° to 38° C. for 1 hour.
15. The method of claim 1 , wherein the complexing agent comprises methylparaben or a salt thereof.
16. The method of claim 1 , wherein the complexing agent comprises propylparaben or a salt thereof.
17. The method of claim 1 , wherein the complexing agent comprises benzoic acid or a salt thereof.
18. The method of claim 1 , wherein the complexing agent comprises methylanthranilate.
19. The method of claim 2 , wherein the concentration of ganaxolone in the dispersion is from about 20 mg/ml to about 150 mg/ml.
20. The method of claim 2 , wherein the concentration of ganaxolone in the dispersion is from about 25 mg/ml to about 75 mg/ml.
21. The method of claim 1 , wherein the preservative is selected from the group consisting of potassium sorbate, methylparaben, propylparaben, benzoic acid, butylparaben, ethyl alcohol, benzyl alcohol, phenol, benzalkonium chloride, and mixtures of any of the foregoing.
22. The method of claim 2 , wherein the liquid oral dosage form contains from about 200 mg to about 500 mg ganaxolone.
23. The method of claim 1 , wherein the complexing agent is one or more parabens.
24. The method of claim 1 , wherein the oral dosage form is a solid dosage form selected from tablets or capsules.
25. The method of claim 1 , wherein the therapeutic dose of ganaxolone incorporated into the oral dosage form is from about 50 mg to about 800 mg.
26. The method of claim 1 , wherein the depression is post-partum depression.
27. A method of treatment for depression, comprising administering to a human patient in need thereof a therapeutically effective amount of an oral dosage form comprising stabilized ganaxolone particles comprising ganaxolone, a hydrophilic polymer in an amount from about 3% to about 50%, w/w, a wetting agent in an amount from about 0.05% to about 2%, w/w, based on the weight of the composition, and a complexing agent selected from the group of small organic molecules having a molecular weight less than 550 and containing a moiety selected from the group consisting of a phenol moiety, an aromatic ester moiety and an aromatic acid moiety, the complexing agent being included in an amount from about 0.05% to about 5%, w/w, based on the weight of the solid particles, wherein the stabilized particles have a volume weighted median diameter (D50) of the particles from about 50 nm to about 500 nm and the concentration of ganaxolone in the solid stabilized particles is at least 50% by weight, wherein the therapeutically effective amount of ganaxolone is sufficient to provide treatment to the human patient suffering from depression.
28. The method of claim 27 , wherein the oral dosage form contains from about 50 mg to about 800 mg ganaxolone.